Investors
Genomic Vision is a publicly-traded company on the Euronext regulated market in Paris
Press release
GENOMIC VISION: CONVENING OF ANOTHER EXTRAORDINARY SHAREHOLDERS’ MEETING ON MARCH 4, 2019
Bagneux (France) – Genomic Vision(FR0011799907 – GV), a company specialized in the development of in-vitrodiagnostic (IVD) tests for the early detection of cancers and genetic diseases and applications for life sciences research (LSR), informs its shareholders that the Extraordinary Shareholders’ Meeting of February 15, 2019 was unable to deliberate, as the required quorum was not met.
The Company would like to thank all the shareholders present at the meeting that enabled to reach a quorum of 18.65%.
The quorum acquired (postal votes and proxies given to the Chairman) at this Extraordinary Shareholders’ Meetingon the first call and valid for the Extraordinary Shareholders’ Meetingon the second call is 17%. The Company is therefore counting on the participation of all its shareholders, individual and institutional, with respect to the Extraordinary Shareholders’ Meetingon the second call in order to vote on the resolutions that will enable the management to continue its development strategy.
The Extraordinary Shareholders’ Meeting on the second call will be held on Monday March 4, 2019 at 9.30 am CET at Simon & Associés, 47 rue de Monceau, 75008 Paris.
All of the documents pertaining to this Extraordinary Shareholders’ Meeting are available in French upon request from GENOMIC VISION, 80 Rue des Meuniers, 92220 Bagneux, France, and can also be found in the Investors / General Assembly section of the Company’s website:
http://www.genomicvision.com/investors/general-assembly.
The votes of shareholders who submitted their votes by post for the first Extraordinary Shareholders’ Meeting remain valid and counted for the Extraordinary Shareholders’ Meeting on the second call.
***
ABOUT GENOMIC VISION
GENOMIC VISION is a company specialized in the development of diagnostic solutions for the early detection of cancers and serious genetic diseases and tools for life sciences research. Through the DNA Molecular Combing, a strong proprietary technology allowing to identify genetic abnormalities, GENOMIC VISION stimulates the R&D productivity of the pharmaceutical companies, the leaders of the diagnostic industry and the research labs.
The Company develops a robust portfolio of diagnostic tests (breast, ovarian and colorectal cancers, myopathies) and analysis tools (DNA replication, biomarkers discovery, gene editing quality control). Based near Paris, in Bagneux, the Company has approximately 50 employees. GENOMIC VISION is a public listed company listed in compartment C of Euronext’s regulated market in Paris (Euronext: GV – ISIN: FR0011799907). For further information, please visit: www.genomicvision.com
Genomic Vision
Aaron Bensimon
Co-fondateur et Président du Directoire
Tél. : +33 1 49 08 07 50
investisseurs@genomicvision.com
Ulysse Communication
Press Relations
Bruno Arabian
Tel. : +33 1 42 68 29 70
barabian@ulysse-communication.com
NewCap
Investor Relations & Strategic Communications
Tel. : +33 1 44 71 94 94
FORWARD LOOKING STATEMENT
This press release contains implicitly or explicitly certain forward-looking statements concerning Genomic Vision and its business.
Such forward-looking statements are based on assumptions that Genomic Vision considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the “Risk Factors” section in its Document de Reference filed with the French Autorité des Marchés Financiers (AMF) on March 28, 2017, under number R.17-009, available on the web site of Genomic Vision (www.genomicvision.com) and to the development of economic conditions, financial markets and the markets in which Genomic Vision operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Genomic Vision or not currently considered material by Genomic Vision. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Genomic Vision to be materially different from such forward-looking statements.
This press release and the information contained herein do not constitute and should not be construed as an offer or an invitation to sell or subscribe, or the solicitation of any order or invitation to purchase or subscribe for Genomic Vision shares in any country. The distribution of this press release in certain countries may be a breach of applicable laws. The persons in possession of this press release must inquire about any local restrictions and comply with these restrictions.
